By Frank Prenesti
Date: Monday 01 Oct 2018
(Sharecast News) - AstraZeneca said it had agreed a $200m deal with Germany's Cheplapharm Arzneimittel for the European commercial rights to Atacand and Atacand Plus heart and hypertension treatments.
| Sunday share tips: AstraZeneca, Genus, 'Dogs of ... | 30-Jul-2017 | ShareCast |
| AstraZeneca co-develops treatment for Alzheimer'... | 09-Dec-2016 | ShareCast |
No recent information was found.
| Questor :AstraZeneca | 29-Apr-2014 | Telegraph |
| Questor : AstraZeneca | 24-Jan-2014 | Telegraph |
| Questor:AstraZeneca | 22-Dec-2011 | Telegraph |
| Investment Column:AstraZeneca | 28-Oct-2011 | The Independent |
| Investment Column: AstraZeneca | 23-Jun-2011 | The Independent |
| Currency | UK Pounds |
| Share Price | 12,455.00p |
| Change Today | -33.00p |
| % Change | -0.26 % |
| 52 Week High | 12,880.00p |
| 52 Week Low | 9,642.00p |
| Volume | 161,601 |
| Shares Issued | 1,264.16m |
| Market Cap | £157,452m |
| Strong Buy | 10 |
| Buy | 13 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 27 |

| Time | Volume / Share Price |
| 09:42 | 160 @ 12,455.00p |
| 09:42 | 59 @ 12,454.00p |
| 09:42 | 7 @ 12,454.00p |
| 09:42 | 30 @ 12,464.00p |
| 09:42 | 15 @ 12,462.00p |
You are here: research